Ruxolitinib, as a JAK1/2 inhibitor, has shown significant efficacy in hematological diseases such as myelofibrosis and polycythemia vera. Its effectiveness has been validated through multiple clinical trials, but its applicability needs to be evaluated based on the specific condition of the patient.

1. Indications and therapeutic effects

(1) Bone marrow fibrosis: can reduce spleen volume, improve systemic symptoms, and prolong the overall survival rate of moderate to high-risk and high-risk patients by 59%.

(2) Polycythemia vera: For patients who are resistant or intolerant to hydroxyurea, the hemoglobin compliance rate increases to over 60%.

2. Mechanism of action

(1) Targeted inhibition of JAK-STAT pathway, blocking abnormal hematopoietic signaling.

(2) Regulate the levels of pro-inflammatory cytokines and improve the tumor microenvironment.

3 Clinical data

(1) The COMFORT-II study showed that at 24 weeks, 35% of patients had a reduction in spleen volume of ≥ 35%.

(2) The Response test confirmed that the control rate of hematocrit was three times higher than that of standard treatment.

4 Precautions for use

(1) Platelet count monitoring is required, and it is contraindicated for patients with severe thrombocytopenia.

(2) May increase the risk of infection, active tuberculosis patients need to complete anti tuberculosis treatment first.